Skip to content

D&A at other companies

TEC
Bio-TechneTECH
$24.17M-12.3%
Revvity logo
RevvityRVTY
$105.06M+7.8%
Danaher logo
DanaherDHR
$193M+6.6%
Agilent Technologies logo
Agilent TechnologiesA
$67M-8.2%
Charles River Laboratories logo
Charles River LaboratoriesCRL
$67.15M-44.2%
WAT
Waters CorporationWAT
$36M+63.6%

Other financials

Income statement

See full
Revenue$194.3M+14.8%
Gross profit$108.3M+18.5%
Operating income$15.9M+142%
Net income$8.3M+42.9%
EPS (diluted)$0.15+50.0%

Balance sheet

See full
Cash & equivalents$582.7M-16.4%
Total debt$687.6M+346%
Total equity$2.1B+6.0%
Total assets$2.9B+2.8%

Cash flow

See full
Operating cash flow$28.3M+88.6%
CapEx$4.7M+32.2%
Free cash flow$23.6M+106%

Valuation

See full
Market cap$7.45B-7.1%
Enterprise value$7.55B+2.1%
P/E144.9×
P/S10.1×-0.1×

Profitability

See full
Gross margin49.5%+2.7pp
Operating margin1.5%-14.0pp
Net margin17.1%-3.7pp
FCF margin21.2%+6.1pp

Returns & leverage

See full
Return on equity2.5%+1.9pp
Debt / equity0.3×+0.2×
Current ratio9.2×+2.4×

Where this comes from

Reported directly by Repligen in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: Repligen’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Repligen's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Repligen's D&A?
Repligen (RGEN) reported D&A of $19.76M in Q1 2026.
How has Repligen's D&A changed year-over-year?
Repligen's D&A increased by 5.7% year-over-year, from $18.7M to $19.76M.
What is the long-term trend for Repligen's D&A?
Over 4 years (2021 to 2025), Repligen's D&A has grown at a 19.6% compound annual growth rate (CAGR), from $38.45M to $78.75M.
What does D&A mean?
Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.